The Effects of Rosiglitazone, Metformin, and Estradiol-Cyproterone Acetate on Lean Patients With Polycystic Ovary Syndrome
Articles > Article · 2009
Authors: Şevki ÇETİNKALP, MUAMMER KARADENİZ, Mehmet ERDOĞAN, Ahmet Gökhan ÖZGEN, Lütfiye Füsun SAYGILI, CANDEĞER YILMAZ
ENDOCRINOLOGIST, Journal Indexed in SCI Expanded, International, 2009, vol 19, pp 94-97
DOI: 10.1097/ten.0b013e3181a58772
Summary
Background: Polycystic ovary syndrome (PCOS) is characterized by anovulation, infertility, and hyperandrogenism. The present study aims to compare the clinical, biochemical, and hormonal changes in PCOS patients taking estradiol-cyproterone acetate (ECA), metformin (MET), and rosiglitazone (ROSI).